Valencia Technologies develops solutions for treating bladder dysfunction. Its eCoin implantable tibial nerve stimulation (ITNS) device treats urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB). It marks another major acquisition for the company’s Urology portfolio, which added Axonics in 2024.
eCoin carries FDA approval, having won the nod in 2022. The coin-sized device is placed under the skin, near the ankle, in a minimally invasive procedure. Valencia designed the device for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or for patients who are intolerant to or have an inadequate response to more conservative UUI treatments.
Once implanted, the device intermittently and automatically stimulates the tibial nerve to help regulate how the brain communicates with the bladder. A clinical trial demonstrated 68% patient responding with at least a 50% reduction in UUI episodes. Valencia was in the news in early 2025 when it raised $35 million to support eCoin.
Boston Scientific expects to close the acquisition in the first half of 2026. It anticipates an immaterial impact on its adjusted earnings per share in 2026 and a more dilutive impact on a GAAP basis.
“The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business,” said Meghan Scanlon, SVP and president, Urology, Boston Scientific. “ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum.”
